Bausch + Lomb (BLCO) Revenue & Revenue Breakdown
Bausch + Lomb Revenue Highlights
Latest Revenue (Y)
$4.15B
Latest Revenue (Q)
$1.22B
Main Segment (Y)
Device Products
Main Geography (Y)
United States and Puerto Rico
Bausch + Lomb Revenue by Period
Bausch + Lomb Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $4.15B | 10.03% |
| 2022-12-31 | $3.77B | 0.08% |
| 2021-12-31 | $3.77B | 10.35% |
| 2020-12-31 | $3.41B | -9.69% |
| 2019-12-31 | $3.78B | 3.08% |
| 2018-12-31 | $3.67B | - |
Bausch + Lomb generated $4.15B in revenue during NA 2023, up 10.03% compared to the previous quarter, and up 113.12% compared to the same period a year ago.
Bausch + Lomb Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.22B | 10.65% |
| 2024-03-31 | $1.10B | -6.31% |
| 2023-12-31 | $1.17B | 16.48% |
| 2023-09-30 | $1.01B | -2.71% |
| 2023-06-30 | $1.03B | 11.17% |
| 2023-03-31 | $931.00M | -6.53% |
| 2022-12-31 | $996.00M | 5.73% |
| 2022-09-30 | $942.00M | 0.11% |
| 2022-06-30 | $941.00M | 5.85% |
| 2022-03-31 | $889.00M | -11.19% |
| 2021-12-31 | $1.00B | 5.48% |
| 2021-09-30 | $949.00M | 1.61% |
| 2021-06-30 | $934.00M | 6.02% |
| 2021-03-31 | $881.00M | -6.67% |
| 2020-12-31 | $944.00M | - |
Bausch + Lomb generated $1.22B in revenue during Q2 2024, up 10.65% compared to the previous quarter, and up 130.61% compared to the same period a year ago.
Bausch + Lomb Revenue Breakdown
Bausch + Lomb Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| Device Products | $1.65B | - |
| Branded and Other Generic Products | $252.00M | - |
| Other Revenues | $15.00M | - |
| Over the Counter Products | $1.61B | - |
| Pharmaceutical Products | $618.00M | - |
| Product | - | $3.75B |
| Product and Service, Other | - | $22.00M |
Bausch + Lomb's latest annual revenue breakdown by segment (product or service), as of Dec 23: Device Products (39.80%), Over the Counter Products (38.86%), Pharmaceutical Products (14.91%), Branded and Other Generic Products (6.08%), and Other Revenues (0.36%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Over the Counter Products | $447.00M | $395.00M | $1.20B | $408.00M | - | - | - | - | - | - |
| Device Products | $445.00M | $424.00M | $1.24B | $411.00M | - | - | - | - | - | - |
| Pharmaceutical Products | $245.00M | $209.00M | $505.00M | $113.00M | - | - | - | - | - | - |
| Branded and Other Generic Products | $76.00M | $66.00M | $180.00M | $72.00M | - | - | - | - | - | - |
| Other Revenues | $3.00M | $5.00M | $12.00M | $3.00M | - | - | - | - | - | - |
| Product and Service, Other | - | - | - | - | $4.00M | $3.00M | $5.00M | $5.00M | $6.00M | $6.00M |
| Product | - | - | - | - | $1.03B | $928.00M | $991.00M | $937.00M | $935.00M | $883.00M |
Bausch + Lomb's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Over the Counter Products (36.76%), Device Products (36.60%), Pharmaceutical Products (20.15%), Branded and Other Generic Products (6.25%), and Other Revenues (0.25%).
Bausch + Lomb Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| Other Countries | $655.00M | $572.00M |
| MEXICO | $68.00M | $55.00M |
| KOREA, REPUBLIC OF | $46.00M | $44.00M |
| JAPAN | $187.00M | $192.00M |
| ITALY | $82.00M | $72.00M |
| GERMANY | $147.00M | $138.00M |
| FRANCE | $210.00M | $195.00M |
| CHINA | $344.00M | $343.00M |
| CANADA | $110.00M | $101.00M |
| United States and Puerto Rico | $1.93B | $1.70B |
| SPAIN | $85.00M | $77.00M |
| POLAND | $51.00M | $44.00M |
Bausch + Lomb's latest annual revenue breakdown by geography, as of Dec 23: United States and Puerto Rico (49.35%), Other Countries (16.71%), CHINA (8.78%), FRANCE (5.36%), JAPAN (4.77%), GERMANY (3.75%), CANADA (2.81%), SPAIN (2.17%), ITALY (2.09%), MEXICO (1.74%), POLAND (1.30%), and KOREA, REPUBLIC OF (1.17%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Other Countries | $175.00M | $166.00M | $214.00M | $150.00M | $152.00M | $139.00M | $157.00M | $142.00M | $138.00M | $126.00M |
| GERMANY | $40.00M | $42.00M | $32.00M | $33.00M | $40.00M | $42.00M | $32.00M | $30.00M | $33.00M | $43.00M |
| ITALY | $23.00M | $23.00M | $21.00M | $19.00M | $22.00M | $20.00M | $15.00M | $16.00M | $21.00M | $20.00M |
| FRANCE | $64.00M | $60.00M | $45.00M | $47.00M | $62.00M | $56.00M | $41.00M | $43.00M | $56.00M | $55.00M |
| CHINA | $93.00M | $77.00M | $94.00M | $87.00M | $89.00M | $74.00M | $92.00M | $93.00M | $76.00M | $82.00M |
| JAPAN | $43.00M | $42.00M | $48.00M | $45.00M | $46.00M | $48.00M | $49.00M | $46.00M | $47.00M | $50.00M |
| KOREA, REPUBLIC OF | $11.00M | $12.00M | $11.00M | $12.00M | $12.00M | $11.00M | $11.00M | $11.00M | $11.00M | $11.00M |
| MEXICO | $20.00M | $17.00M | $18.00M | $19.00M | $15.00M | $16.00M | $16.00M | $14.00M | $14.00M | $11.00M |
| CANADA | $32.00M | $28.00M | $30.00M | $27.00M | $27.00M | $26.00M | $28.00M | $27.00M | $24.00M | $22.00M |
| POLAND | $18.00M | $15.00M | $14.00M | $11.00M | $14.00M | $12.00M | $11.00M | $10.00M | $12.00M | $11.00M |
| SPAIN | $25.00M | $21.00M | $23.00M | $18.00M | $24.00M | $20.00M | $21.00M | $15.00M | $22.00M | $19.00M |
| United States and Puerto Rico | $610.00M | $537.00M | $593.00M | $471.00M | $466.00M | $404.00M | $454.00M | $425.00M | $430.00M | $386.00M |
| AUSTRALIA | - | - | - | $11.00M | $11.00M | $10.00M | - | - | - | - |
| SWEDEN | - | - | - | - | - | - | - | - | - | $9.00M |
Bausch + Lomb's latest quarterly revenue breakdown by geography, as of Jun 24: United States and Puerto Rico (52.86%), Other Countries (15.16%), CHINA (8.06%), FRANCE (5.55%), JAPAN (3.73%), GERMANY (3.47%), CANADA (2.77%), SPAIN (2.17%), ITALY (1.99%), MEXICO (1.73%), POLAND (1.56%), and KOREA, REPUBLIC OF (0.95%).
Bausch + Lomb Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BDX | Becton, Dickinson and Company | $19.37B | $4.99B |
| ALC | Alcon | $10.09B | $2.46B |
| RMD | ResMed | $4.69B | $1.20B |
| BLCO | Bausch + Lomb | $4.15B | $1.22B |
| HOLX | Hologic | $4.03B | $1.01B |
| COO | Cooper Companies | $3.59B | $1.00B |
| ATR | AptarGroup | $3.49B | $910.06M |
| TFX | Teleflex | $2.97B | $749.69M |
| WST | West Pharmaceutical Services | $2.95B | $702.00M |
| ICUI | ICU Medical | $2.26B | $596.46M |
| HAE | Haemonetics | $1.31B | $336.17M |
| ATRC | AtriCure | $399.25M | $116.27M |
| ANGO | AngioDynamics | $303.91M | $75.18M |
| AKYA | Akoya Biosciences | $96.63M | $23.16M |
| ATRI | Atrion | - | $48.77M |
BLCO Revenue FAQ
What is Bausch + Lomb’s yearly revenue?
Bausch + Lomb's yearly revenue for 2023 was $4.15B, representing an increase of 10.03% compared to 2022. The company's yearly revenue for 2022 was $3.77B, representing an increase of 0.08% compared to 2021. BLCO's yearly revenue for 2021 was $3.76B, representing an increase of 10.35% compared to 2020.
What is Bausch + Lomb’s quarterly revenue?
Bausch + Lomb's quarterly revenue for Q2 2024 was $1.22B, a 10.65% increase from the previous quarter (Q1 2024), and a 17.49% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.1B, a -6.31% decrease from the previous quarter (Q4 2023), and a 18.05% increase year-over-year (Q1 2023). BLCO's quarterly revenue for Q4 2023 was $1.17B, a 16.48% increase from the previous quarter (Q3 2023), and a 17.77% increase year-over-year (Q4 2022).
What is Bausch + Lomb’s revenue growth rate?
Bausch + Lomb's revenue growth rate for the last 3 years (2021-2023) was 10.12%, and for the last 5 years (2019-2023) was 9.74%.
What are Bausch + Lomb’s revenue streams?
Bausch + Lomb's revenue streams in c 23 are Device Products, Branded and Other Generic Products, Other Revenues, Over the Counter Products, and Pharmaceutical Products. Device Products generated $1.65B in revenue, accounting 39.80% of the company's total revenue Branded and Other Generic Products generated $252M in revenue, accounting 6.08% of the company's total revenue Other Revenues generated $15M in revenue, accounting 0.36% of the company's total revenue Over the Counter Products generated $1.61B in revenue, accounting 38.86% of the company's total revenue Pharmaceutical Products generated $618M in revenue, accounting 14.91% of the company's total revenue
What is Bausch + Lomb’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Bausch + Lomb was Device Products. This segment made a revenue of $1.65B, representing 39.80% of the company's total revenue.